A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Randomized, Open-label, Food Effect Study of HEC73077 in Healthy Subjects
Latest Information Update: 14 Apr 2023
At a glance
- Drugs HEC 73077 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 11 Apr 2023 Status changed from recruiting to completed.
- 16 Aug 2022 New trial record